01510nam a2200241   45000010005000000100015000051000041000201010008000612000158000692100083002272150017003102250040003273000132003673300542004996060022010416060034010636060033010976060022011306060012011526060024011647100069011888520011012577583  a9291681229  a20030115d2002       y0pory50      ba  aeng  aReport on the risk assessment of GHB in the framework of the joint action on new synthetic drugsfEuropean Monitoring Centre for Drugs and Drug Addiction  aLuxembourgcOffice for Official Publications of the European Communitiesd2002  a92 p.d21 cm  aImplemention of the joint actionv4  aInformação sobre European Monitoring Centre for Drugs and Drug Addiction pode ser encontrada no site: https://www.emcdda.org  aReport on the risk assessment of GHB in the framework of the joint action on new synthetic drugs. Europol-EMCDDS progress report on GHB in accordance with Article 3 of the joint action of 16 June 1997 concerning the information exchange, risk assessment and the control of new synthetic drugs. Use of GHB as a medicinal product (EMEA). Review of the pharmacotoxicological data on gamma-hydroxybutyric acid (GHB). Sociological and criminological (Europol) evidence on the risk of GHB. Public health risk of GHB - epidemiological evidence.  aDROGAS ILÍCITAS  aSUBSTÂNCIAS PSICOTRÓPICAS  aCOOPERAÇÃO INTERNACIONAL  aSAÚDE PÚBLICA  aEUROPOL  aCONSELHO DA  EUROPA  aEUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION - EMCDDA  jDRO321